

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

HEp-2

RRID:CVCL_1906

Type: Cell Line

Proper Citation

CCTCC Cat# GDC0004, RRID:CVCL_1906

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1906

Proper Citation: CCTCC Cat# GDC0004, RRID:CVCL_1906

Description: Cell line HEp-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related endocervical adenocarcinoma

Defining Citation: [PMID:566722](#), [PMID:1246601](#), [PMID:3180844](#), [PMID:4203458](#), [PMID:4864103](#), [PMID:5641128](#), [PMID:5668122](#), [PMID:6988327](#), [PMID:8397027](#), [PMID:11416159](#), [PMID:13209540](#), [PMID:13261081](#), [PMID:14185313](#), [PMID:17254797](#), [PMID:19450234](#), [PMID:19941903](#), [PMID:20143388](#), [PMID:23925245](#), [PMID:25485619](#), [PMID:26589293](#), [PMID:29483928](#), [PMID:29967540](#), [PMID:31105993](#), [PMID:33389257](#), [PMID:34024160](#), [PMID:34697958](#)

Comments: Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257)., Population: African American., Part of: KuDOS 95 cell line panel., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from a 56 year old male patient with a laryngeal carcinoma..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEp-2

Synonyms: Hep-2, HEP-2, Hep2 (HeLa derivative), HEp-2/HeLa, Hep 2, Hep2, HEp2, HEP2, H.Ep.-2, H.Ep. #2, H.Ep. No. 2, Hep II, Human Epidermoid carcinoma #2, Human

Epithelioma-2

Cross References: BTO:BTO_0000976, CLO:CLO_0003706, CLO:CLO_0003707, CLO:CLO_0050927, EFO:EFO_0006438, CLDB:cl1646, CLDB:cl1647, CLDB:cl1649, CLDB:cl1650, CLDB:cl1653, CLDB:cl1654, CLDB:cl1655, AddexBio:C0050001/4983, ArrayExpress:E-MTAB-2706, ATCC:CCL-23, BCRC:60042, BCRJ:0101, BioSample:SAMN03151706, CCLV:CCLV-RIE 0141, CCRID:1101HUM-PUMC000068, CCRID:4201PAT-CCTCC00214, CCTCC:GDC0004, Cell_Model_Passport:SIDM01208, ChEMBL-Cells:ChEMBL3307694, ChEMBL-Targets:ChEMBL614735, CLS:300397, Cosmic:1339928, Cosmic:1530739, Cosmic:1969495, Cosmic:2301559, ECACC:86030501, EGA:EGAS00001000610, FANTOM5_SSTAR:11890-125D9, FANTOM5_SSTAR:11891-125E1, FANTOM5_SSTAR:11892-125E2, FANTOM5_SSTAR:11894-125E4, FANTOM5_SSTAR:11895-125E5, FANTOM5_SSTAR:11896-125E6, FANTOM5_SSTAR:11898-125E8, FANTOM5_SSTAR:11899-125E9, FANTOM5_SSTAR:11900-125F1, GEO:GSM1374529, GEO:GSM1374530, IZSLER:BS TCL 23, KCLB:10023, NCBI_Iran:C144, PharmacDB:HEp2_540_2019, PRIDE:PXD006201, PRIDE:PXD013072, PRIDE:PXD014913, PRIDE:PXD031726, PubChem_Cell_line:CVCL_1906, RCB:RCB1889, TKG:TKG 0403, TOKU-E:1442, Wikidata:Q16554737

ID: CVCL_1906

Vendor: CCTCC

Catalog Number: GDC0004

Hierarchy: cvcl_0030

Record Creation Time: 20220427T220333+0000

Record Last Update: 20260905T180247+0000

Ratings and Alerts

No rating or validation information has been found for HEp-2.

Warning: Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from a 56 year old male patient with a laryngeal carcinoma.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00007.

Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257)., Population: African American., Part of: KuDOS 95 cell line panel., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from a 56 year old male patient with a laryngeal carcinoma.. **Warning:** Discontinued: BCRC; 60042

Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257)., Population: African American., Part of: KuDOS 95 cell line panel., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally

thought to originate from a 56 year old male patient with a laryngeal carcinoma..

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 2898 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Abu-Shmais AA, et al. (2026) A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein. *Cell reports. Medicine*, 7(2), 102564.

Weiskirchen R, et al. (2026) Genetic Insights into the Economic Toll of Cell Line Misidentification: A Comprehensive Review. *Medical sciences (Basel, Switzerland)*, 14(1).

Yang Q, et al. (2026) Molecular mechanism of resistance to Ionafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a Ionafarnib-derived antiviral PROTAC. *Journal of virology*, 100(1), e0148725.

Lønskov J, et al. (2026) Viral infection and brain inflammation with seizures in PARK7 deficiency. *Journal of human immunity*, 2(2), e20250044.

Koutstaal RW, et al. (2026) Respiratory Syncytial Virus Nonstructural Protein 1 Inhibits Production of Cytokines and Chemokines by Differentiated Primary Nasal Epithelial Cells Cultured at Air-Liquid Interface. *Journal of innate immunity*, 18(1), 188.

Yang K, et al. (2026) Rhein inhibits respiratory syncytial virus entry by stabilizing the prefusion conformation of the fusion protein. *Journal of advanced research*.

Donlic A, et al. (2026) Deep learning of functional perturbations from condensate morphology. *Cell*, 189(15), 4562.

Farías MA, et al. (2026) Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody. *EBioMedicine*, 123, 106104.

Dreyer HHM, et al. (2026) Small molecule-directed differentiation of submerged-cultured human nasal airway epithelia for respiratory disease modeling. *Cell reports. Medicine*, 7(4), 102692.

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Rodríguez-Guilarte L, et al. (2026) Regulation of antiviral immunity by PD-1 during respiratory syncytial virus infection and upon vaccination. *iScience*, 29(6), 116157.

Haas de Mello A, et al. (2025) Respiratory syncytial virus downregulates the airway aryl hydrocarbon receptor pathway: implication for the development of a novel therapeutic target. *American journal of physiology. Lung cellular and molecular physiology*, 329(6), L716.

Liedtke V, et al. (2025) Linking LEDGF/p75 Overexpression With Microsatellite Instability and KRAS Mutations: A Small-Scale Study in Colorectal Cancer. *Cancer control : journal of the Moffitt Cancer Center*, 32, 10732748251313499.

Wu X, et al. (2025) Development of a neutralization assay and bioluminescent imaging mouse model for Dehong virus (DEHV) using a pseudovirus system. *Microbiology spectrum*, 13(5), e0155724.

Toumi E, et al. (2025) GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model. *British journal of pharmacology*, 182(16), 3786.

Van Nederveen V, et al. (2025) Enterοaggregative Escherichia coli (EAEC). *EcoSal Plus*, eesp00112024.

Fortin A, et al. (2025) No evidence of direct activation of human neutrophil responses by multivalent prefusion trimeric SARS-CoV-2 Spike protein ex vivo. *PloS one*, 20(10), e0332261.

Bizzoca ME, et al. (2024) Methods for Overcoming Chemoresistance in Head and Neck Squamous Cell Carcinoma: Keeping the Focus on Cancer Stem Cells, a Systematic Review. *Cancers*, 16(17).

Scharffenberger SC, et al. (2024) Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. *Cell reports*, 43(10), 114811.

Mommert-Tripon M, et al. (2024) Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection. *EBioMedicine*, 110, 105450.